MorphoSys AG: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million)Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 millionPreliminary unaudited financial

Related Keywords

Germany ,Boston ,Massachusetts ,United States ,Canada ,Munich ,Bayern ,Planegg ,Kaitlyn Nealy ,Thomas Biegi ,Julia Neugebauer ,Jean Paul Kress ,Morphosys Agview ,Exchange Commission ,Us Communications ,Linkedin ,Xencor Inc ,Twitter ,Drug Administration ,Financial Liabilities ,Chief Executive Officer ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Morphosy Annual Report ,Investor Relations ,Morphosys ,Reports ,Reliminary ,022 ,Monjuvi ,Product ,Sales ,Rovides ,023 ,Financial ,Guidance ,Educes ,Liability ,